Codexis Inc (CDXS)

$1.23 -0.03 (-2.38%)
Market Cap 111.10M
Revenue (ttm) 59.35M
Net Income (ttm) -65.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -109.99%
Debt to Equity Ratio 1.03
Volume 1,779,700
Avg Vol 1,256,426
Day's Range N/A - N/A
Shares Out 90.32M
Stochastic %K 82%
Beta 2.49
Analysts Strong Sell
Price Target $6.58

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 421 8100
Address:
200 Penobscot Drive, Redwood City, United States
Fingerlickengood
Fingerlickengood Mar. 6 at 9:45 PM
$CDXS Analyzing all the data, considering the financial status of the company, and now having a clearly stated path forward per the CEO, I believe once the Q4 / EOY earnings are released and management officially projects 2026 objectives/financial outlook, the share price should quickly recover bringing this back stabilizing around a $300M+ market cap!
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 6 at 3:05 PM
$CDXS https://www.investmentreports.co/interview/alison-moore-2223
0 · Reply
Jdnguyen24
Jdnguyen24 Mar. 6 at 6:28 AM
$CDXS https://www.linkedin.com/posts/codexis_biocatalysis-greenchemistry-pharmabiocatalysis-activity-7435457904817823744-ha2A?utm_medium=ios_app&rcm=ACoAAAHhN3MBs8ivg0vpCOMEz4uefk0ydzCGLjo&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 10:42 PM
$CDXS $NVS "On Friday, that company was revealed to be Atrium, which is starting out with programs for two rare, life-threatening heart conditions: PRKAG2 syndrome and PLN cardiomyopathy. Both are in preclinical testing. The company also has two other undisclosed research targets and about $270 million in cash to work with. "
2 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 10:39 PM
$CDXS While I had previously suggested Corsera Health could be the 'unnamed' player buying the 50g of siRNA from Codexis, I believe there maybe even a bigger argument it could be Novartis' spinout company Atrium! $NVS and Codexis have a longstanding partnership though their technology transfer of CodeEvolver! https://www.biopharmadive.com/news/atrium-avidity-spinout-novartis-rna-cardiomyopathy-heart/813365/
0 · Reply
momtrepreneur
momtrepreneur Mar. 5 at 9:56 PM
$DSY $GBR $CDXS $MOBX 👀👀👀🚀🚀🤑🤑🤑
0 · Reply
buymoremakemore
buymoremakemore Mar. 5 at 9:54 PM
$CDXS congrats to those who bought the dip. I will be buying a bunch tomorrow. I think on good q4/q1 this goes above $2 again
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 6:09 PM
$CDXS Kind of a BIG deal! Why? Because Codexis signed a supply agreement with Molecular Assemblies that was later then acquired by Maravai LifeSciences! $MRVI https://patents.justia.com/assignee/codexis-inc
4 · Reply
Bondra
Bondra Mar. 5 at 5:54 PM
$CDXS This dogwater company is single handedly holding up my portfolio today lmao
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 3:22 PM
$CDXS Longs here know they made some fundamental mistakes end of last quarter and the way the information was presented to investors. The stock took a beating for it and I highly doubt history will repeat in six days when the Q4 / EOY earnings are released and the conference calls takes place !
1 · Reply
Latest News on CDXS
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Mar 4, 2026, 10:06 AM EST - 3 days ago

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

Feb 25, 2026, 9:00 AM EST - 10 days ago

Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

Codexis Achieves ISO 9001:2015 Certification

Feb 10, 2026, 9:00 AM EST - 25 days ago

Codexis Achieves ISO 9001:2015 Certification

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

Jan 7, 2026, 9:00 AM EST - 2 months ago

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Nov 10, 2025, 9:00 AM EST - 4 months ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 2:16 PM EST - 4 months ago

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Oct 29, 2025, 9:58 AM EDT - 4 months ago

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Codexis to Report Third Quarter 2025 Financial Results on November 6

Oct 23, 2025, 7:05 AM EDT - 4 months ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Codexis to Participate in Cantor Global Healthcare Conference

Aug 28, 2025, 9:00 AM EDT - 6 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:57 PM EDT - 7 months ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Codexis Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Codexis Reports Second Quarter 2025 Financial Results

Codexis to Report Second Quarter 2025 Financial Results on August 13

Jul 30, 2025, 4:05 PM EDT - 7 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 22, 2025, 7:00 AM EDT - 10 months ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Codexis to Participate in Jefferies Global Healthcare Conference

May 21, 2025, 4:05 PM EDT - 10 months ago

Codexis to Participate in Jefferies Global Healthcare Conference

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 6:50 PM EDT - 10 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Codexis Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 10 months ago

Codexis Reports First Quarter 2025 Financial Results

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

May 7, 2025, 7:00 AM EDT - 10 months ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Codexis Announces Byron Dorgan to Retire from Board of Directors

Apr 9, 2025, 5:00 PM EDT - 11 months ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

Codexis Announces New Employment Inducement Grants

Mar 7, 2025, 4:05 PM EST - 1 year ago

Codexis Announces New Employment Inducement Grants

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:20 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 13, 2025, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Feb 6, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Codexis Appoints Christos Richards to Board of Directors

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Codexis to Participate in Upcoming Healthcare Conferences

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:48 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Codexis Publishes FY2023 Sustainability Disclosures

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 14, 2024, 6:00 AM EDT - 1 year ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:24 PM EDT - 2 years ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Apr 11, 2024, 7:05 AM EDT - 2 years ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:39 PM EST - 2 years ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 4:05 PM EST - 2 years ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 4:05 PM EST - 2 years ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:05 AM EST - 2 years ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 20, 2024, 8:05 AM EST - 2 years ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 14, 2024, 4:05 PM EST - 2 years ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Fingerlickengood
Fingerlickengood Mar. 6 at 9:45 PM
$CDXS Analyzing all the data, considering the financial status of the company, and now having a clearly stated path forward per the CEO, I believe once the Q4 / EOY earnings are released and management officially projects 2026 objectives/financial outlook, the share price should quickly recover bringing this back stabilizing around a $300M+ market cap!
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 6 at 3:05 PM
$CDXS https://www.investmentreports.co/interview/alison-moore-2223
0 · Reply
Jdnguyen24
Jdnguyen24 Mar. 6 at 6:28 AM
$CDXS https://www.linkedin.com/posts/codexis_biocatalysis-greenchemistry-pharmabiocatalysis-activity-7435457904817823744-ha2A?utm_medium=ios_app&rcm=ACoAAAHhN3MBs8ivg0vpCOMEz4uefk0ydzCGLjo&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 10:42 PM
$CDXS $NVS "On Friday, that company was revealed to be Atrium, which is starting out with programs for two rare, life-threatening heart conditions: PRKAG2 syndrome and PLN cardiomyopathy. Both are in preclinical testing. The company also has two other undisclosed research targets and about $270 million in cash to work with. "
2 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 10:39 PM
$CDXS While I had previously suggested Corsera Health could be the 'unnamed' player buying the 50g of siRNA from Codexis, I believe there maybe even a bigger argument it could be Novartis' spinout company Atrium! $NVS and Codexis have a longstanding partnership though their technology transfer of CodeEvolver! https://www.biopharmadive.com/news/atrium-avidity-spinout-novartis-rna-cardiomyopathy-heart/813365/
0 · Reply
momtrepreneur
momtrepreneur Mar. 5 at 9:56 PM
$DSY $GBR $CDXS $MOBX 👀👀👀🚀🚀🤑🤑🤑
0 · Reply
buymoremakemore
buymoremakemore Mar. 5 at 9:54 PM
$CDXS congrats to those who bought the dip. I will be buying a bunch tomorrow. I think on good q4/q1 this goes above $2 again
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 6:09 PM
$CDXS Kind of a BIG deal! Why? Because Codexis signed a supply agreement with Molecular Assemblies that was later then acquired by Maravai LifeSciences! $MRVI https://patents.justia.com/assignee/codexis-inc
4 · Reply
Bondra
Bondra Mar. 5 at 5:54 PM
$CDXS This dogwater company is single handedly holding up my portfolio today lmao
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 3:22 PM
$CDXS Longs here know they made some fundamental mistakes end of last quarter and the way the information was presented to investors. The stock took a beating for it and I highly doubt history will repeat in six days when the Q4 / EOY earnings are released and the conference calls takes place !
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 5 at 3:03 PM
$CDXS Word is on the street!
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 4 at 8:31 PM
$CDXS At yesterday ‘s Cowens investor presentation CEO Allison Moore confirmed GMP buildout cost will be between $20M to $25M and ‘they have the funding to complete’ AS WELL AS a cash runway that extends into 2027!
1 · Reply
mikesterz7
mikesterz7 Mar. 4 at 7:14 PM
$CDXS The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 4 at 6:53 PM
$CDXS “ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication” Fairly confident this is the drug candidate not identified in today’s PR!
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 4 at 5:51 PM
Why Did CDXS Stock Jump 7% Today? $CDXS $IBB $IWO $IWC https://stocktwits.com/news/equity/markets/why-did-cdxs-stock-jump-7-today/cZd9tTURIdd
0 · Reply
focafoca99
focafoca99 Mar. 4 at 5:47 PM
$CDXS signed agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform.
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 4 at 5:40 PM
$CDXS Geddy up! https://www.biospace.com/press-releases/corsera-health-files-first-phase-1-clinical-trial-application-for-its-lead-preventive-rnai-medicine-program-for-cardiovascular-disease
0 · Reply
10xMoonstocks
10xMoonstocks Mar. 4 at 4:28 PM
$CDXS Anyone have any insight into what kind of revenue this will generate? I just finished listening to the call. I was fairly neutral on the company, but after listening to the call and seeing the announcement I'm back to being bullish again!
3 · Reply
Jdnguyen24
Jdnguyen24 Mar. 4 at 4:12 PM
$CDXS Results! https://ir.codexis.com/news-events/press-releases/detail/442/codexis-signs-agreement-to-manufacture-50-g-sirna-using-its-eco-synthesis-manufacturing-platform
0 · Reply
Camille65
Camille65 Mar. 4 at 3:45 PM
$CDXS The design win for 50g siRNA drug announced today (4th March), fair to speculate for Corsera Health? They are due to start dosing soon for dosing in a Phase 1 clinical trial of COR-1004, a novel subcutaneously administered siRNA targeting PCSK9.
1 · Reply
Camille65
Camille65 Mar. 4 at 3:39 PM
$CDXS Merck PDFUA date for their hp drug scheduled for April. Is that one of the two expected approved drugs that will need Codexis enzymes 9as mentioned by the CEO, 2 approval in 2026)
0 · Reply
Camille65
Camille65 Mar. 4 at 3:35 PM
$CDXS The CEO (at TD Cowen 3rd March) mentioned one CDMO currently in tech transfer for ECO and the next step would be licensing (suspect it's Bachem). the CEO also mention engagment with a customer in phase III siRNA (suspect Lilly which is already contracted phase III to Bachem). Is the setting right for future usage of ECO by Bachem for Lilly siRNA drug?
0 · Reply